Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 81 to 90 of 220 total matches.

Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015  (Issue 1470)
on or after platinumbased chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after ...
The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda), and the first to be approved for treatment of NSCLC.
Med Lett Drugs Ther. 2015 Jun 8;57(1470):85-7 |  Show IntroductionHide Introduction

Invader UGT1A1 Molecular Assay for Irinotecan Toxicity

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
........................................p 39 A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan ...
The FDA has approved a new genetic test to identify patients who may be at increased risk of severe toxicity when treated with the cancer chemotherapy drug irinotecan (Camptosar). The Invader UGT1A1 Molecular Assay (Third Wave Technologies) detects the UGT1A1*28 allele, a variation in the uridine diphosphate glucuronosyltranferase 1A1 (UGT1A1) gene. The FDA recently revised the safety labeling for irinotecan, recommending that the dosing of irinotecan be reduced for patients who are homozygous for the UGT1A1*28 allele.
Med Lett Drugs Ther. 2006 May 8;48(1234):40 |  Show IntroductionHide Introduction

Medical Marijuana

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2010  (Issue 1330)
) have both been FDA-approved since 1985 for treatment of chemotherapy-induced nausea and vomiting ...
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa). In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Med Lett Drugs Ther. 2010 Jan 25;52(1330):5-6 |  Show IntroductionHide Introduction

Dolutegravir (Tivicay) for HIV

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013  (Issue 1426)
on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 9- 12, 2012. Available at www.natap.org ...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):77-9 |  Show IntroductionHide Introduction

Albumin-Bound Paclitaxel (Abraxane) for Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. 1 ...
A new albumin-bound formulation of paclitaxel (Abraxane - American Pharmaceutical Partners) has been approved by the FDA for treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. This formulation is free of polyoxyethylated castor oil (Cremophor), a solvent thought to contribute to the hypersensitivity reactions that occur frequently with standard paclitaxel (Taxol, and others) and are severe in about 3% of patients.
Med Lett Drugs Ther. 2005 May 9;47(1208):39-40 |  Show IntroductionHide Introduction

Eribulin Mesylate (Halaven) for Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011  (Issue 1362)
at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included ...
Eribulin mesylate (Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda), gemcitabine (Gemzar, and others) and vinorelbine (Navelbine, and others).
Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1 |  Show IntroductionHide Introduction

Umbilical Cord Blood for Bone Marrow Transplantation

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996  (Issue 981)
FOR ONLINE USERS UMBILICAL CORD BLOOD FOR BONE MARROW TRANSPLANTATION High-dose chemotherapy followed ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Med Lett Drugs Ther. 1996 Aug 16;38(981):71-2 |  Show IntroductionHide Introduction

Palifermin (Kepivance) for Myelotoxic-Therapy-Related Mucositis

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005  (Issue 1207)
myelotoxic chemotherapy and hematopoietic stem cell support. It appears to be well tolerated and could ...
Palifermin (Kepivance - Amgen), a recombinant human keratinocyte growth factor (KGF), has been approved by the FDA to decrease the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic chemotherapy and hematopoietic stem cell (HSC) rescue.
Med Lett Drugs Ther. 2005 Apr 25;47(1207):36 |  Show IntroductionHide Introduction

Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
mirvetuximab soravtansine or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topetecan ...
Mirvetuximab soravtansine-gynx (Elahere – Immuno-Gen), an antibody-drug conjugate, has received accelerated approval by the FDA for treatment of folate receptor (FR) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy. Accelerated approval was based on the overall response rate and median duration of response.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e205-6 |  Show IntroductionHide Introduction

Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
infusion of lifileucel (7.5 x 109 - 72 x 109 viable cells) after lymphodepleting chemotherapy. ▶ Cost ...
Lifileucel (Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma previously treated with a programmed death receptor-1 (PD-1) inhibitor, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a mitogen-activated kinase (MEK) inhibitor. It is the first cellular therapy to be approved for use in solid tumors. Accelerated approval of lifileucel was based on objective response rates.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e77-8   doi:10.58347/tml.2024.1701h |  Show IntroductionHide Introduction